| |
Download our latest fact sheet to see how Catalent’s cell line development platform delivers unmatched efficiency, stability, and yield. Download Now. 
|
|
Today’s Big NewsJun 17, 2025 |
|
In a capital-constrained environment, equipment financing offers a smart and flexible path forward. NFS Capital is here to help you keep innovating without waiting for your next funding round. Request more information. .png)
|
|
| By James Waldron Eli Lilly confirms its buyout of Verve Therapeutics after reports about the deal were published by the Financial Times Monday. |
|
|
|
By Gabrielle Masson The FDA is introducing a new priority voucher program designed to shorten the drug review process time from 10 to 12 months down to one or two months, according to the agency. |
By Gabrielle Masson Antares may be forging ahead with Scorpion's leadership team, but the company is adopting a different approach designed to account for the drastic transformation in both the biotech and macroeconomic environments. |
Sponsored by Thermo Fisher Scientific Austin Read of Thermo Fisher Scientific discusses how combining biospecimens with real-world data is advancing diagnostics, treatment and the future of patient care. |
|
Septemeber 8-11, 2025 | Philadelphia, PA Join the industry's top minds at Fierce Pharma Week—where innovation, strategy, and partnerships converge. Don’t miss your chance to lead the future of pharma. Register Today. 
|
|
By Nick Paul Taylor Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that will inform whether Sanofi takes up its right of first negotiation on the NLRP3 inhibitor. |
By James Waldron Mineralys Therapeutics’ aldosterone synthase inhibitor has chalked up a third clinical win in recent months, demonstrating once again its potential to reduce blood pressure in patients with hypertension. |
By James Waldron Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around for cash to prevent the company from going bust. |
By Angus Liu The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend an Inflation Reduction Act provision currently affecting treatments for rare diseases. |
By Angus Liu China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time that regulators take to review clinical trials. |
By Darren Incorvaia A federal judge in Massachusetts has ruled that hundreds of grants terminated by the National Institutes of Health must be immediately restored, the latest legal victory for groups challenging the Trump administration’s extreme cuts to federal science funding. |
By Darren Incorvaia As Harvard University reels from extensive cuts to federal funding by the Trump Administration, one researcher there has secured his lab’s future by looking abroad. Gökhan Hotamışlıgil, M.D., Ph.D., has secured about $39 million from a Turkish investment group to support the next 10 years of his group’s research on new antibodies for obesity and other metabolic diseases. |
By Gabrielle Masson,Darren Incorvaia As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. |
By Kevin Dunleavy Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer treatment Venclexta. |
By Conor Hale A defective speaker resulted in some Dexcom G7, G6 and One CGM users missing audio alarms for unhealthy blood sugar levels. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we unpack Fierce Medtech's Fierce 15 and spotlight startups reimagining healthcare. |
|
|---|
|
|
|
A pipeline-supporting marketing plan that includes proven tools, well-executed tactics, and a clear strategy are key to keeping your pipeline full of qualified leads. Access this valuable resource to discover how your marketing team can support your business development team in three essential areas: audience, storytelling, and performance. Download today! 
|
|
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
